Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany

Company also commits to investing up to $100 million in German early-stage life sciences ecosystem

20-Nov-2023
Lilly Deutschland GmbH

Preliminary design of Lilly's high-tech production facility in Alzey

Eli Lilly and Company announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company's global parenteral (injectable) product and device manufacturing network and support an increased demand for Lilly's medicines, including its diabetes and obesity portfolio. The company has launched 21 treatments since 2014 and plans to launch several more in the coming years.

"Every investment into our manufacturing capacity around the world is a renewed commitment to patients today – and to those who may need our medicines tomorrow," said Edgardo Hernandez, executive vice president and president, Lilly manufacturing operations. "This state-of-the-art parenteral site with the latest technology will enable us to continue to deliver medicines with safety first and quality always around the world." 

With the planned manufacturing facility in Alzey, Lilly will operate a total of six manufacturing sites in Europe, including one in nearby Fegersheim, France. Lilly's ongoing investments in Europe will create operational synergies, strengthen university and government relationships, support the early-stage life science ecosystem, and diversify the growing Lilly presence in Europe.

With extensive experience across the pharmaceutical industry, Germany's workforce will play a vital role in bolstering Lilly's incretin supply when the new site is operational beginning in 2027. The site in Alzey will employ up to 1,000 highly skilled workers such as engineers, operators and scientists, who will leverage state-of-the-art technology, including automation and high-speed manufacturing lines, to produce life-changing medicines. In addition, an estimated 1,900 jobs will be created during construction, which is scheduled to begin in 2024. Lilly's investment in Alzey is contingent upon finalization of government permitting and local approvals.

"The decision to locate here is good news for Germany as a business location," said Dr. Robert Habeck, vice chancellor and federal minister for Economic Affairs and Climate Action. "It creates new and future-oriented jobs, shows the confidence of companies in the attractiveness of Germany as a pharmaceutical and industrial location and helps to improve healthcare for our citizens. The new location will make an important contribution to industrial value creation in Germany with high-tech production facilities and research and development."

Lilly has announced investments of more than $11 billion in its global manufacturing footprint in the past three years to help ensure the safe and reliable supply of Lilly's innovative medicines. The company continues to invest in the expansion of its global manufacturing to address the growth expected from potential new medicines to treat diabetes and obesity, Alzheimer's disease, cancer and autoimmune conditions.

"As we look to usher in the next generation of medicines, we're looking for people and partners who share our passion for improving health outcomes," said Ilya Yuffa, executive vice president and president, Lilly International. "With this new investment, we hope to spark a new era of collaboration and innovation in Germany and the European Union defined by our shared purpose to find lasting solutions for patients."

The company is also announcing an investment of up to $100 million to dramatically increase its footprint in Germany's early-stage biotech ecosystem. These investments will focus on biotech and the life sciences venture capital funds – expanding Lilly's incubator and accelerator engagements, and strengthening Lilly's ties and activities with world-renowned academic and innovation partners. With these investments, Lilly will pursue strategic partnerships and collaborations utilizing a variety of models that meet a range of business needs, including capital and equity investments; world-class lab space; and outstanding research and development capabilities and expertise to help accelerate innovative medicines that meet the needs of people globally.

"This investment strengthens the Federal Government in its efforts to make Germany more attractive again as a pharmaceutical location," added Prof. Dr. Karl Lauterbach, federal minister of health. "It shows good innovative products can be reliably developed and produced in Germany. But we will continue to improve the framework conditions for research and production. This will ensure that patients have rapid access to new treatment options and make us more independent from fragile supply chains. Europe needs a strong pharmaceutical industry and research – not least for good and secure healthcare. Germany wants to provide new stimuli here."

Other news from the department manufacturing

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.

Last viewed contents

Vitamin K may protect against developing non-Hodgkin's lymphoma, say Mayo Clinic researchers

Novasep opens new 2,000 m2 expanded Shanghai facilities to meet increasing East Asia demand - New site increases Novasep’s process development and engineering capabilities to supply turnkey purification processes in East Asia

Merck to Develop Abituzumab in Metastatic Colorectal Cancer with SFJ Pharmaceuticals Group

Scientists identify enzymes that create a highly toxic form of mercury in Antarctic sea ice

Scientists identify enzymes that create a highly toxic form of mercury in Antarctic sea ice

CO2 for a clean performance: Rheticus research project by Evonik and Siemens enters phase 2 - High-value specialty chemicals produced from CO2 and water using electricity from renewable sources and bacteria

CO2 for a clean performance: Rheticus research project by Evonik and Siemens enters phase 2 - High-value specialty chemicals produced from CO2 and water using electricity from renewable sources and bacteria

Roche Joins in Spanish Research Cooperation for Personalized Treatment of Hepatitis B and C

Neuroscientists illuminate how brain cells deep in the cortex operate in freely moving mice - This new miniature microscope is a game changer for exploring the link between neural activity and complex animal behavior

Neuroscientists illuminate how brain cells deep in the cortex operate in freely moving mice - This new miniature microscope is a game changer for exploring the link between neural activity and complex animal behavior

Scientists create compounds that dramatically alter biological clock and lead to weight loss - The new molecules could lead to unique treatments for obesity, diabetes, high cholesterol, and sleep disorders

QIAGEN and Bio*One Capital Enter into Joint Venture to Develop Molecular Diagnostics Products - Assay development centre for Singapore will support QIAGEN in the market for molecular testing solutions

Researchers Identify Genetic Mutation That May Alter Patients' Response to Cancer Therapeutics - Recurring mutation found in breast, colorectal and ovarian cancers

OctoPlus wins drug development and manufacturing contract from Danish pharmaceutical company

'An underutilized tool:' UV-LED lights can kill coronaviruses and HIV with the flip of a switch - A Toronto-based start-up company that partnered for the study, is developing unique UV-LED lighting modules

'An underutilized tool:' UV-LED lights can kill coronaviruses and HIV with the flip of a switch - A Toronto-based start-up company that partnered for the study, is developing unique UV-LED lighting modules